Antithrombin iii human for antithrombin iii deficiency

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Oct 2023: Trial registered, NCT06096116
  2. 21 Aug 2024: Trial started, NCT06096116

The trials

NCT06096116: Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

State
Under way
Phase
Phase 3
People
120 planned
Started
21 Aug 2024
Primary completion
Mar 2028
Arms
Low-dose Atenativ, High-dose Atenativ
Results
None posted
  1. 23 Oct 2023: Trial registered
  2. 21 Aug 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Atenativ, Atnativ, Antithrombin concentrate (ATIIIC), Kybernin, Kybernin p, Thrombate iii.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.